AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9145856 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine sulfate (15 mg/kg)
Number of subjects: 16
Study 8181328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipratropium and albuterol
Number of subjects: 534
Study 8181328 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium
Number of subjects: 534
Study 8181328 — intervention group
Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 534
Study 3695494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxymesterone (5 mg p.o. b.i.d.) for 3 days before and on the day of chemotherapy
Number of subjects: 75
Study 3695494 — intervention group
Group type: COMPARATOR
Intervention: Cyclic i.v. chemotherapy with cytoxan, adriamycin and 5-fluorouracil
Number of subjects: 75
Study 3695494 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no androgen priming)
Number of subjects: 75
Study 3695494 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation arm (with androgen priming)
Number of subjects: 75
Study 30539767 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized moderate intensity 12-week aerobic or weight-bearing exercise program
Number of subjects: 17
Study 26636547 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in cannabis use
Number of subjects: 332
Study 24968966 — intervention group
Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 72
Study 23379542 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week comprehensive lifestyle modification program (CLMP) in addition to standard care
Number of subjects: 29
Study 23379542 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 29
Study 21489065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention video identifying the artificial nature of media images
Number of subjects: 127
Study 21489065 — intervention group
Group type: COMPARATOR
Intervention: Control images (non-thin models)
Number of subjects: 127
Study 21489065 — intervention group
Group type: COMPARATOR
Intervention: Ultra-thin models exposure without intervention
Number of subjects: 127
Study 18691861 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-containing treatment
Number of subjects: 0
Study 18691861 — intervention group
Group type: COMPARATOR
Intervention: Formoterol treatment
Number of subjects: 0
Study 18691861 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline St George's Respiratory Questionnaire (SGRQ) total score
Number of subjects: 0
Study 18691861 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-item short-form health survey (SF-36) scores
Number of subjects: 0
Study 17318445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation and linear lesions
Number of subjects: 100
Study 17318445 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein isolation alone
Number of subjects: 100
Study 12668406 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 375
Study 12668406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 12668406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus exposure therapy
Number of subjects: 375
Study 12668406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline alone
Number of subjects: 375
Study 12668406 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy alone
Number of subjects: 375
Study 10708933 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/day)
Number of subjects: 10
Study 10708933 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/day)
Number of subjects: 10
Study 10708933 — intervention group
Group type: COMPARATOR
Intervention: Atenolol and Propranolol
Number of subjects: 10
Study 9543786 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (3 doses)
Number of subjects: 26
Study 9543786 — intervention group
Group type: COMPARATOR
Intervention: Primary vaccination (3 doses)
Number of subjects: 26
Study 9543786 — intervention group
Group type: COMPARATOR
Intervention: Booster vaccination (1 dose) after vaccination 7 years earlier
Number of subjects: 26
Study 9543786 — intervention group
Group type: COMPARATOR
Intervention: Control group with immune status based on past infection (3 doses)
Number of subjects: 26
Study 1556672 — intervention group
Group type: EXPERIMENTAL
Intervention: Beighton's, Carter's and Rotés' HMS scores
Number of subjects: 114
Study 1556672 — intervention group
Group type: EXPERIMENTAL
Intervention: New scale for defining HMS
Number of subjects: 114
Study 1556672 — intervention group
Group type: EXPERIMENTAL
Intervention: Major HMS items
Number of subjects: 114
Study 1556672 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic set of criteria to define HMS
Number of subjects: 114
Study 3310339 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 52
Study 3310339 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 52
Study 30701736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (30 mg/day for 2 days and 1 day before PCI, 20 mg 2 hours before PCI, 10 mg 6 hours after PCI)
Number of subjects: 88
Study 30701736 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 88
Study 27296040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated concurrent chemoradiotherapy (CRT) with tumor doses of 63 to 73 Gy in 30 once-daily fractions over 6 weeks with 2 concurrent cycles of cisplatin and vinorelbine.
Number of subjects: 84
Study 23868679 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 72
Study 23868679 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic plus Resistance Training (AT + RT)
Number of subjects: 72
Study 23868679 — intervention group
Group type: COMPARATOR
Intervention: Leisure Physical Activity (LPA)
Number of subjects: 72
Study 22506530 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed toolkit
Number of subjects: 315
Study 22506530 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit and a brief guide to the toolkit's content
Number of subjects: 315
Study 22506530 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 315
Study 19944650 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO-01 (morphine sulfate and naltrexone hydrochloride)
Number of subjects: 113
Study 19944650 — intervention group
Group type: COMPARATOR
Intervention: Extended-release morphine sulfate (ERMS)
Number of subjects: 113
Study 19944650 — intervention group
Group type: COMPARATOR
Intervention: ALO-01 and ERMS
Number of subjects: 113
Study 19944650 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO-01
Number of subjects: 113
Study 18678581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature art (art images dominated by natural vegetation, flowers or water)
Number of subjects: 225
Study 18678581 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 225
Study 16946602 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluoride interventions
Number of subjects: 15
Study 16946602 — intervention group
Group type: COMPARATOR
Intervention: Cluster-randomized trials
Number of subjects: 15
Study 16946602 — intervention group
Group type: COMPARATOR
Intervention: Sample size calculation
Number of subjects: 15
Study 12659989 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethazidine (60 mg) + Diltiazem (90 mg)
Number of subjects: 50
Study 11126034 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine (0.7 mg/kg) or midazolam (0.035 mg/kg) intravenously
Number of subjects: 50
Study 11126034 — intervention group
Group type: COMPARATOR
Intervention: no medication (control group)
Number of subjects: 50
Study 9366538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteric jet index (calculated from colour Doppler ultrasound)
Number of subjects: 31
Study 9366538 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintigraphic index (found using Patlak‐Rutland graphical analysis)
Number of subjects: 31
Study 9366538 — intervention group
Group type: COMPARATOR
Intervention: Comparison of jet index and scintigraphic index
Number of subjects: 31
Study 9366538 — intervention group
Group type: COMPARATOR
Intervention: Discrepancies in scores
Number of subjects: 31
Study 9366538 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of renal artery stenosis
Number of subjects: 31
Study 1388878 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU nHuIFN alpha once daily orally for 6 weeks
Number of subjects: 30
Study 1388878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3902200 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and 5‐fluorouracil)
Number of subjects: 117
Study 3902200 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF and tamoxifen (TMX)
Number of subjects: 117
Study 3902200 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF and medroxyprogesterone (MAP)
Number of subjects: 117
Study 3902200 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (doxorubicin) (ADX) vincristine (VCR) and TMX
Number of subjects: 117
Study 3902200 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (doxorubicin) (ADX) vincristine (VCR) and MAP
Number of subjects: 117
Study 3902200 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to both treatments
Number of subjects: 117
Study 3902200 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 117
Study 28830853 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugarsquare (web-based patient portal)
Number of subjects: 105
Study 28830853 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study 26133200 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially covered SEMS
Number of subjects: 103
Study 26133200 — intervention group
Group type: COMPARATOR
Intervention: Uncovered SEMS
Number of subjects: 103
Study 23768685 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT)
Number of subjects: 799
Study 23768685 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiotherapy (CRT)
Number of subjects: 799
Study 23768685 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 799
Study 23768685 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute organ toxicity
Number of subjects: 799
Study 23768685 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 799
Study 21635992 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg, BID for 12 weeks
Number of subjects: 588
Study 21635992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 19840695 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic tailored intervention (targeted psychosocial determinants)
Number of subjects: 1971
Study 19840695 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmentally tailored intervention (intervention-plus)
Number of subjects: 1971
Study 19840695 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 1971
Study 16461961 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 31897
Study 16461961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 31897
Study 16461961 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 31897
Study 16117955 — intervention group
Group type: EXPERIMENTAL
Intervention: Lambdacyhalothrin residual house spraying (25 mg/m²)
Number of subjects: 39
Study 16117955 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 39
Study 10773777 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysymptomatic (PS) cases
Number of subjects: 44
Study 10773777 — intervention group
Group type: COMPARATOR
Intervention: Monosymptomatic (MS) cases
Number of subjects: 44
Study 9596981 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine 1 g/d (58 subjects)
Number of subjects: 96
Study 9596981 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1 g/d (38 subjects)
Number of subjects: 96
Study 8257205 — intervention group
Group type: EXPERIMENTAL
Intervention: Low power laser treatment (12 J/cm2 for 30 s, 12 treatments over four weeks)
Number of subjects: 25
Study 8257205 — intervention group
Group type: COMPARATOR
Intervention: Sham laser treatment
Number of subjects: 25
Study 3928053 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple insulin injections
Number of subjects: 0
Study 3928053 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump
Number of subjects: 0
Study 29723339 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated growth factor (CGF)
Number of subjects: 20
Study 29723339 — intervention group
Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM)
Number of subjects: 20
Study 28253079 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (α2‐adrenoceptor antagonist)
Number of subjects: 0
Study 28253079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0
Study 28253079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28253079 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (Yohimbine and Hydrocortisone)
Number of subjects: 0
Study 25768023 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare intervention (data uploaded daily to a nurse-led monitoring station)
Number of subjects: 171
Study 25768023 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 171
Study 23311705 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 74
Study 23311705 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 74
Study 21614630 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with documented allergies
Number of subjects: 521
Study 21614630 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with accurate allergy documentation
Number of subjects: 521
Study 21614630 — intervention group
Group type: COMPARATOR
Intervention: Patients with no allergy documentation
Number of subjects: 521
Study 18686184 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokeless tobacco plus group support
Number of subjects: 263
Study 18686184 — intervention group
Group type: COMPARATOR
Intervention: Group support only
Number of subjects: 263
Study 16497687 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective CPAP
Number of subjects: 23
Study 16497687 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 23
Study 16497687 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline OSA patients
Number of subjects: 23
Study 14600550 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EX): 50 min of treadmill walking at 65% of heart rate reserve for 10 consecutive days
Number of subjects: 32
Study 14600550 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 32
Study 14600550 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EX)
Number of subjects: 32
Study 9862844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0
Study 9862844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9862844 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 0
Study 8554251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 g of lactulose)
Number of subjects: 25
Study 8554251 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 25
Study 8554251 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (fermentable fiber)
Number of subjects: 25
Study 8554251 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcellulose (nonfermentable fiber)
Number of subjects: 25
Study 8554251 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fiber preparations and lactulose
Number of subjects: 25
Study 1864100 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (0.5 mg) inhaled with positive expiratory pressure (PEP)
Number of subjects: 0
Study 1864100 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (0.5 mg) inhaled without PEP
Number of subjects: 0
Study 1864100 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray inhaled with PEP
Number of subjects: 0
Study 6191298 — intervention group
Group type: EXPERIMENTAL
Intervention: VAT pacing
Number of subjects: 14
Study 6191298 — intervention group
Group type: EXPERIMENTAL
Intervention: V-CWS-T pacing
Number of subjects: 14
Study 6191298 — intervention group
Group type: COMPARATOR
Intervention: VOO mode at 70 beats per minute
Number of subjects: 14
Study 29417384 — intervention group
Group type: EXPERIMENTAL
Intervention: Agave fructans (96 mg/bw for 12 weeks)
Number of subjects: 28
Study 29417384 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo for 12 weeks)
Number of subjects: 28
Study 26997623 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein isolates (60 g/day)
Number of subjects: 79
Study 26997623 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (60 g/day)
Number of subjects: 79
Study 24296850 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 112
Study 24296850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 22964958 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 73
Study 22964958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 20581351 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (1 g/day) and Vitamin E (400 IU/day) supplementation during pregnancy
Number of subjects: 0
Study 20581351 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C preincubation
Number of subjects: 0
Study 20581351 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C alone
Number of subjects: 0
Study 20581351 — intervention group
Group type: COMPARATOR
Intervention: TNF incubation
Number of subjects: 0
Study 17962619 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention with darbepoetin alfa (300 microg every 3 weeks)
Number of subjects: 201
Study 17962619 — intervention group
Group type: COMPARATOR
Intervention: Observation group (delayed intervention)
Number of subjects: 201
Study 17962619 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention with darbepoetin alfa
Number of subjects: 201
Study 17962619 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention subgroup (received darbepoetin alfa later)
Number of subjects: 201
Study 17962619 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention subgroup
Number of subjects: 201
Study 17962619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 201
Study 16287955 — intervention group
Group type: EXPERIMENTAL
Intervention: Edifoligide
Number of subjects: 3014
Study 16287955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3014
Study 12121931 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg i.v. b.i.d. on day 1 followed by 3 mg/kg i.v. b.i.d. on days 2 to 7, then switched to 200 mg orally b.i.d. for days 8 to 14
Number of subjects: 42
Study 12121931 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg i.v. b.i.d. on day 1 followed by 5 mg/kg i.v. b.i.d. on days 2 to 7, then switched to 400 mg orally b.i.d. for days 8 to 14
Number of subjects: 42
Study 12121931 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg i.v. b.i.d. on day 1 followed by 4 mg/kg i.v. b.i.d. on days 2 to 7, then switched to 300 mg orally b.i.d. for days 8 to 14
Number of subjects: 42
Study 12121931 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 42
Study 12121931 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole treatment
Number of subjects: 42
Study 10633514 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized anesthesia delivery system
Number of subjects: 57
Study 10633514 — intervention group
Group type: COMPARATOR
Intervention: Traditional anesthesia delivery system
Number of subjects: 57
Study 10633514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 57
Study 7861219 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine (50 mg every 6 hours)
Number of subjects: 101
Study 7861219 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 101
Study 2019922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk formula without added iron
Number of subjects: 854
Study 2019922 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 854
Study 2019922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk formula with added iron
Number of subjects: 854
Study 2019922 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dextran injection
Number of subjects: 854
Study 7181805 — intervention group
Group type: EXPERIMENTAL
Intervention: Benactyzine hydrochloride (intramuscular administration)
Number of subjects: 6
Study 31907009 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacy Practice Model (CPPM)
Number of subjects: 720
Study 31907009 — intervention group
Group type: COMPARATOR
Intervention: Usual care process
Number of subjects: 720
Study 31907009 — intervention group
Group type: EXPERIMENTAL
Intervention: CPPM
Number of subjects: 720
Study 31533151 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic Suspension Allograft (ASA)
Number of subjects: 200
Study 31533151 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA)
Number of subjects: 200
Study 31533151 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 200
Study 28196583 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic screening through pulse palpation
Number of subjects: 7000
Study 28196583 — intervention group
Group type: COMPARATOR
Intervention: Active search for symptomatic patients
Number of subjects: 7000
Study 26782527 — intervention group
Group type: EXPERIMENTAL
Intervention: Short ultrasound (10 min)
Number of subjects: 60
Study 26782527 — intervention group
Group type: EXPERIMENTAL
Intervention: Long ultrasound (20 min)
Number of subjects: 60
Study 26782527 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 24463662 — intervention group
Group type: COMPARATOR
Intervention: 25-hydroxyvitamin D concentrations <30 nmol/L
Number of subjects: 792
Study 24463662 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations 50-74 nmol/L
Number of subjects: 792